ODAN LEVOCARNITINE SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

LEVOCARNITINE

から入手可能:

ODAN LABORATORIES LTD

ATCコード:

A16AA01

INN（国際名）:

LEVOCARNITINE

投薬量:

100MG

医薬品形態:

SOLUTION

構図:

LEVOCARNITINE 100MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

CALORIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0127168003; AHFS:

認証ステータス:

APPROVED

承認日:

2019-09-09

製品の特徴

PRODUCT MONOGRAPH
Pr
ODAN LEVOCARNITINE
Levocarnitine Oral Solution, USP
100 mg / mL
Amino Acids and Derivatives
Odan Laboratories Ltd.
325 Stillview Avenue
Pointe-Claire, QC
H9R 2Y6
Date of Preparation:
September 5, 2019
Submission Control No:222026
ODAN LEVOCARNITINE Product Monograph
Page 2 of 21
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
.............................................................................
10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................11
STORAGE AND STABILITY
.........................................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
..............................................................................................................
16
DETAILED PHARMACOLOGY
..........................................